HUMANIZED PAN-HER ANTIBODY COMPOSITIONS

• 1. 人源化泛HER抗体组合物 [P] . 中国专利： CN104428318B . 2018.09.25
• 2. 人源化泛HER抗体组合物 [P] . 中国专利： CN104428318A . 2015-03-18
• 3. HUMANIZED PAN-HER ANTIBODY COMPOSITIONS [P] . 欧洲知识产权局专利： EP2844675B1 . 2019-01-02

  机译： 人性化的泛HER抗体组合物

• 4. HUMANIZED PAN-HER ANTIBODY COMPOSITIONS [P] . 美国专利： US2018344846A1 . 2018-12-06

  机译： 人性化的泛HER抗体组合物

• 5. Humanized pan-her antibody compositions [P] . AU2013255537B2 . 2018-02-15

  机译： 人源化pan-her抗体组合物

• 1. Specific Immunotherapy in Advanced Cervical-Uterine Cancer Using Humanized Monoclonal Antibody Nimotuzumab and CIMAvax-EGF®;Therapeutic Vaccine [J] . Raiza Ruiz-Lorente, Sayly Alfonso, Eduardo Santiesteban, 癌症治疗（英文） . 2021,第003期
• 2. The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma [J] . Christian Beth A., Poi Ming, Jones Jeffrey A., British Journal of Haematology . 2015,第5期
• 3. Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs [J] . Tejaswini P. Reddy, Dong S. Choi, Ann C. Anselme, Breast Cancer Research . 2020,第1期
• 4. Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity [J] . Jacobsen Helle J., Poulsen Thomas T., Dahlman Anna, Clinical cancer research: an official journal of the American Association for Cancer Research . 2015,第18期
• 5. DEVELOPMENT OF A HUMANIZED ANTI-CEA ANTIBODY FOR FLUORESCENT GUIDED SURGERY OF GI CANCERS [C] . Paul J. Yazaki, Thinzar M. Lwin, Megan Minnix, Molecular-Guided Surgery: Molecules, Devices, and Applications V . 2019
• 6. Comparative analysis of humanized antibodies with small changes in either the heavy chain or light chain of the antibody [D] . Rajendran, Sakthi Harini. 2016
• 7. Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs [O] . Tejaswini P. Reddy, Dong S. Choi, Ann C. Anselme, 2020
• 8. Pan-HER - an antibody mixture targeting EGFR, HER2, and HER3 abrogates preformed and ligand-induced EGFR homo- and heterodimers:Pan-HER abrogates EGFR dimers [O] . Ellebaek Sofie, Pedersen Susanne Brix, Grandal Michael, 2016

• 1. Induction of Human Anti-Human Antibody Responses (Ab2) after Application of a Humanized Lewis Y Carbohydrate Specific Antibody (Ab1): Connection of Prolonged Disease Stabilization with Ab3 Induction? [J] . Andreas Nechansky ,Stefan Stranner ,Oliver Scheiber . 癌症治疗（英文） . 2012,第4期
• 2. Safety and Therapeutic Efficacy of the Lewis Y Carbohydrate Specific Humanized Antibody MB311 in Patients with Malignant Effusion [J] . Thomas Bauernhofer ,Helmut Samonigg ,Peter Regitnik . 癌症治疗（英文） . 2014,第1期
• 3. Phase I Dose Escalation Study with the Lewis Y Carbohydrate Specific Humanized Antibody IGN311 [J] . Daniel Oruzio ,Gunter Waxenecker ,Christoph Aulmann . 癌症治疗（英文） . 2011,第5期
• 4. Preparation and activity analysis of the divalent and tetravalent humanized V_H single domain antibody against human lung cancer [J] . JIE PING WANG ,JIANG HUA YAN ,CHANG GONG ZHANG . 中华微生物学和免疫学：英文版 . 2007,第2期
• 5. 基于泛证券投资组合理论与K搜索的程序化交易策略构建 [C] . 张文明 ,孙廉琏 . 管理科学与工程学会2017年年会暨第十五届中国管理科学与工程论坛 . 2017
• 6. 泛癌症分析及基于泛癌症分子标志物的肿瘤预后模型构建 [A] . 胡朔枫 . 2017